Synklino

Synklino is a preclinical-stage biotech targeting a critical unmet need in transplant medicine: cytomegalovirus (CMV) infection. The company is developing SYN002, a therapeutic aimed at eliminating CMV from donor organs prior to transplantation (ex vivo) or treating recipients afterward (in vivo), with proof-of-concept data recently published. Founded by experienced life science veterans, Synklino operates as a private, pre-revenue company leveraging a focused scientific approach and an international network to advance its pipeline for chronic viral infections.

A platform for developing drug candidates targeting latent viral reservoirs, with an initial application enabling ex vivo treatment of donor organs during normothermic machine perfusion to eliminate cytomegalovirus.

Competes with standard-of-care antivirals (e.g., valganciclovir) and other companies developing next-generation antivirals or immunotherapies for CMV prophylaxis. Synklino's primary differentiation is its focused ex vivo approach, which aims to eliminate the virus at the source (the donor organ) rather than systemically suppressing it in the patient post-transplant.